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Abstract
The new iodine complex (FS-1), including molecular iodine, which is coordinated by 
lithium, magnesium halides, and bioorganic ligands, possesses high bactericidal activity 
against various microorganisms, including Mycobacterium sp., Staphylococcus aureus MRSA 
and MSSA, Escherichia coli, Pseudomonas aeruginosa, etc. FS-1 has synergistic properties with 
a broad class of antibiotics. The experimental model of tuberculosis in guinea pigs caused 
by clinical multidrug-resistant strains of Mycobacterium tuberculosis shows antituberculosis, 
immunomodulatory, and anti-inflammatory activity. FS-1 is characterized by low acute 
toxicity and lack of genotoxicity and mutagenicity. FS-1 is well distributed to organs and 
tissues; its pharmacokinetics is linear. The maximum nontoxic dose is 100 mg/kg for rats 
after 28-day oral administration and 30 mg/kg for rabbits after 180-day oral administration.
Keywords: Mycobacterium tuberculosis, iodine, complex, antimicrobial activity, 
antimicrobial resistance, tuberculosis, antituberculosis drug, preclinical trials, toxicity
1. Introduction
Antimicrobial resistance (AMR) has long been recognized as a global problem [1, 2]. At that, 
the solution to this problem is complicated by the fact that as soon as a new antibiotic appears, 
it is immediately reported about resistance to it. For example, some isolates of Pseudomonas 
aeruginosa and Burkholderia cenocepacia showed intermediate resistance to a new antibiotic 
eravacycline as early as at the stage of clinical trials, although the antibiotic effectiveness is 
very high against other bacteria, including the multiresistant ones [3]. Sometimes this resis-
tance can be natural, for example, to pyrazinamide in Mycobacterium bovis [4, 5]. A widely 
practiced method of reducing AMR, the cyclic and mixed use of antibiotics that belong to 
alternative classes, has proved to be ineffective [6].
© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
Pulmonary tuberculosis poses a particular problem. The global WHO report announced the 
number of new tuberculosis cases detected in 2015—2110.4 million, of which 480,000 new 
cases of multidrug-resistant tuberculosis (MDR-TB) and 7579 cases of extensively drug-
resistant TB (XDR-TB). The greatest number of the disease cases is registered in six coun-
tries—India, Indonesia, China, Nigeria, Pakistan, and South Africa—60% of the worldwide 
incidence [7]. Despite the emergence of new antituberculosis drugs, the situation with high 
resistance of M. tuberculosis remains difficult [7, 8]. In this regard, the search and development 
of new anti-infectious drugs are extremely relevant.
Among the numerous substances with high antimicrobial activity, resistance to which was 
not detected or it remains at the minimum level, there are polymeric complexes of iodine 
[9, 10]. Iodine complexes have broad antimicrobial, anti-inflammatory, immunomodula-
tory, and antitumor activity [11–16]. Really interesting are nanocomposites with molecular 
iodine, which are superior in their antimicrobial activity to the widely known complex of 
polyvinylpyrrolidone and iodine (PVP-iodine) [17, 18]. The ability of molecular iodine 
to form complexes with a variety of properties and compositions with ligands of differ-
ent nature makes it very promising to develop drugs based on iodine coordination com-
pounds [19–24].
The new drug FS-1 relates to iodine coordination compounds with bioorganic ligands, mag-
nesium, and lithium cations. The active center of FS-1 included α-dextrin helix with molecular 
iodine (I
2
) that is coordinated with lithium halogenides and amide groups of protein com-
ponent. Such a structure protects I
2
 from interaction with bioorganic compounds after oral 
intake. Bioorganic compounds are only able to compete with I
2
 in complexing if donor activity 
is greater as against amide groups [24–26].
The developed drug FS-1 possesses broad antimicrobial activity against antibiotic-resistant 
and antibiotic-susceptible Gram-positive and Gram-negative bacteria, mycobacteria, fungi, 
and viruses [27–33].
Both liquid and solid dosage forms of FS-1 were produced from the pharmaceutical develop-
ment process [34]. Preclinical trials of the drug FS-1 were conducted according to the recom-
mendations of the International Conference on Harmonization of Technical Requirements for 
Registration of Pharmaceuticals for Human Use (ICH). This chapter will present the major 
results from preclinical trials of the new drug FS-1, conducted in 2004–2014.
2. In vitro antimicrobial activity
The aim of these studies presented here was to assess the in vitro antimicrobial activity of 
FS-1. By using a serial dilution technique assay, the activities of FS-1 were tested against both 
on typified bacteria and on clinical isolates. Table 1 shows a list of microorganisms that were 
used to examine the in vitro effectiveness of FS-1 [27–29, 33, 35, 36].
The minimum inhibitory concentration (MIC) was in the range of 0.02–0.3 mg/mL. At 
the same time, clinical isolates M. tuberculosis SCAID 187.0 (MDR); 562, 892, 535, and 722 
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(isoniazid-resistant); and M. bovis 2, 3, and 5 showed the greatest susceptibility [36]. The MIC 
of FS-1 against Y. pestis and B. anthracis was 0.2 mg/mL [35].
FS-1 causes lysis of the bacterial cell, damaging the cell membrane [37]. A study on the mem-
brane lytic activity of FS-1 on M. smegmatis by electron microscopy showed that the bacterial 
cell lysis occurs within 5–30 minutes at a concentration of FS-1 of 4 μg/mL. In addition, FS-1 
inhibits DNA-dependent RNA polymerase (RNAP) of M. tuberculosis forming a complex 
between bacterial DNA and magnesium ion in RNAP [26].
Most bacterial diseases including tuberculosis are treated with a combination of multiple 
drugs in a regimen. Synergistic effects with existing drugs are valuable characteristics of a 
new drug candidate. FS-1 was tested in combination with antibiotics and various first and 
second antituberculosis drugs (ATBD). Synergy between drugs and FS-1 was determined by 
chequerboard in vitro [27]. Testing showed that synergy between FS-1 and antituberculo-
sis drugs (ATBD) was observed against both on susceptibility and on multidrug resistance 
MTB. Among the cephalosporins, only сefamandole showed synergy with FS-1 against 
clinical isolates S. aureus. The index of fractional inhibitory concentration was 0.62 [27]. Thus, 
according to the results of testing, in vitro the FS-1 is an effective compound of a class of 
iodine coordination compounds.
3. In vivo antituberculosis activity
The most important stage of preclinical studies of new drugs is the evaluation of efficacy in 
animal models. There are various animal M. tuberculosis infection models. The most com-
mon are guinea pigs and mice. A classical guinea pig model of tuberculosis caused by highly 
Typified bacteria Clinical isolates
M. tuberculosis H37Rv* M. tuberculosis MS-115 (MDR), SCAID 
187.0 (MDR); 562, 892, 535, and 722* 
(isoniazid-resistant); M. bovis** 2, 3, and 5; 
M. avium 780
Yersinia pestis***, Bacillus anthracis***, 
Brucella sp.***
Staphylococcus aureus ATCC 6538-Р В-RКМ 0039, S. aureus ATCC 29213—
oxacillin-susceptible strain (MSSA), S. aureus ATCC 43300—methicillin- 
and oxacillin-resistant (MRSA), S. aureus ATCC 29213, S. aureus ATCC 
43300, Escherichia coli ATCC 25922, and ATCC BAA-196 and Candida 
albicans ATCC 18814
S. aureus****—114 MRSA and MSSA clinical 
isolates—P. aeruginosa № 4/32, E. coli O55 
№ 12, C. albicans 3/4
*Collections of microorganisms at the National Scientific Center for Pulmonology, Kazakhstan.
**At Kazakh Scientific Research Veterinary Institute.
***At Kazakh Scientific Center for Quarantine and Zoonotic Diseases.
****At Institute of Experimental Pathology and Parasitology, Bulgaria.
Table 1. List of bacteria and their characteristics used to examine antimicrobial activity of FS-1.
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virulent clinical strains of M. tuberculosis MS-115 and SCAID 187.0 isolated from patients with 
MDR-TB was used in the study on the therapeutic effectiveness of FS-1 [8, 29, 38].
The efficacy result of the tuberculosis model showed that the FS-1 combination regimen 
reduced the bacterial load in comparison with standard therapy. A primary characteristic 
of the therapeutic activity of FS-1 was an increase in the effectiveness when combined with 
ATBD including isoniazid, rifampicin, pyrazinamide, cycloserine, protionamide, capreomy-
cin, and amikacin [29, 30]. It was noted that in the treatment of tuberculosis in guinea pigs with 
FS-1 M. tuberculosis acquired susceptibility to first-line ATBD. Apparently this is due to the 
effect of FS-1 on the M. tuberculosis genome [30]. In the studies on other bacteria, Streptococcus 
mutans and S. aureus and S. epidermidis, iodine complexes have been shown to influence the 
transcription activity in microbial genome [39–41].
The therapeutic effect on the guinea pig body has also been noted. In particular, the exposure 
to FS-1 inhibits the development of inflammation in tuberculosis and increases the airiness of 
the lung parenchyma and permeability of capillaries [29]. This is due to the ability of iodine 
complexes to inhibit the production of NO and TNF-alpha and increase mucociliary clearance 
in the respiratory tract [15, 42]. In addition, combination therapy with FS-1 and ATBD reduces 
the incidence of adverse reactions and toxic effects of the drugs in animals [30].
In the studies presented here, the combination of FS-1 in MDR-TB animal models is signifi-
cantly more effective than therapy only with ATBD.
4. Toxicity studies
The toxicity of FS-1 was examined in both liquid form and tablets [34, 43].
The median cytotoxic concentration (CC
50
) of FS-1 on the MDCK cells exceeds 5 mg/mL [44]. 
In vitro and in vivo genotoxicity and mutagenic potential of FS-1 were examined in mice with 
Ames test, micronucleus, and comet assays. According to the results from the studies, FS-1 
does not induce gene mutations or chromosomal abnormalities [45, 46].
Acute toxicity study of FS-1 liquid dosage form was carried out after intravenous administra-
tion to rodents, mice (CD-1), and rats (Wistar) [47]. The median lethal dose (LD
50
) was 65 mg/kg 
in mice and 100 mg/kg in rats. After the administration of FS-1, the following signs were 
observed in animals: exophthalmos, piloerection, impaired motor coordination, paroxysmal 
convulsions of lower limbs, bradycardia, and tachypnea. Death occurred within 24 hours after 
the administration of FS-1. Necropsy revealed a disturbance of blood circulation in the heart, 
liver, and kidneys and pulmonary edema in dead animals. Microscopic examination showed 
plethora and inflammatory infiltration in the lungs, liver, and kidneys and diapedesis hemor-
rhages in the myocardium. At the same time, there were no changes in the thyroid gland [47].
After oral administration of FS-1 liquid form to rats (Wistar), LD
50
 was not achieved. The 
maximum administered dose of FS-1 was 466 mg/kg. The minimal dose of FS-1 did not cause 
damage to the mucous membrane of the gastrointestinal tract (GIT). Medium and high doses 
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provoked minimal damage to the gastric mucosa. Histological examination of thyroid gland 
did not reveal the pathological changes [47].
Toxicokinetics (TK) of FS-1 liquid form was examined in male and female rats after single oral 
administration at doses of 233, 116, and 30 mg/kg [48]. The content of FS-1 was measured in 
the blood, heart, lungs, liver, kidneys, and spleen. The primary TK parameters were calcu-
lated by non-compartmental method. The maximum concentration of FS-1 in the blood (C
max
) 
and the time it was reached (t
max
) were found visually on the graph. The TK parameters for 
oral doses of FS-1 are given in Table 2.
FS-1 is absorbed quite rapidly from the gastrointestinal tract; the maximum values of its 
concentrations in the blood were reached within 1–1.5 hours after its administration. During 
the first 10–30 minutes, the concentration of FS-1 in the blood increased and reached a maxi-
mum after 2 hours. The level of the drug was further reduced, and at the end of 96 hours, 
the detection limit was reached. High values of the volume of distribution, according to the 
generally accepted point of view, can be interpreted as a sign of a wide distribution of the 
drug in the body. At the same time, the rate of distribution of FS-1 in the organs was lower 
than in the blood, therefore, accumulation does not take place. The nature of the relationship 
between the dose of FS-1 and the area under the pharmacokinetic curve (AUC) in the blood, 
as well as the constancy of the invariant TK parameters, indicate that the dynamics of drug 
absorption, distribution, and elimination obey the basic principles of linear kinetics. The 
primary metabolites of FS-1 include iodides, which are excreted in the urine [48].
In addition, chronic toxicity was examined during 180-day oral administration in rabbits. The 
characteristic symptoms of iodine toxicity in rabbits were not detected at a dose of 30 mg/kg 
[47–51].
Despite the fact that iodine does not have mutagenic properties, there is evidence of the effect 
of high iodide doses on the development of mice. Although the mechanisms of toxic effect of 
TK parameter Dose, mg/kg
30 116 233
AUC(mg·h/L) 138.2 ± 19.5 382.4 ± 49.6 669.5 ± 103.1
Cl (L·h/kg) 0.22 ± 0.03 0.30 ± 0.04 0.35 ± 0.05
MRT (h) 24.6 ± 3.5 20.2 ± 2.7 23.1 ± 3.6
β (h−1) 0.026 ± 0.003 0.025 ± 0.004 0.026 ± 0.004
V
β
 (L/kg) 8.2 ± 1.2 12.0 ± 1.6 13.5 ± 2.1
C
max
 (mg/L) 9.0 ± 0.2 34.1 ± 5.0 45.1 ± 9.6
t
max
 (h) 2 1 1
t
1/2(β)
 (h) 26.6 ± 3.7 26.6 ± 3.6 26.6 ± 3.7
Table 2. Toxicokinetic parameters of FS-1 after single oral administration of three doses to rats by non-compartmental 
method, n = 6.
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high iodide doses on pregnant females and embryos have not been revealed, it is assumed 
that this is due to impaired thyroid function in pregnant females. Thyroid hormones in turn 
affect sex glands of animals [52]. An evaluation of the embryotoxic properties of FS-1 was 
performed on a bird model using Gallus gallus chicken embryos at different developmental 
stages [53]. Embryotoxicity was assessed by the effect of FS-1 on survival and developmental 
pathology. At a concentration of 3 mg/mL, the mortality rate of 10-day embryos was 100%, 
whereas for 12- and 18-day-old embryos, it was 80 and 50%, respectively. At the same time, 
developmental abnormalities were not detected. The toxicity of FS-1 toward chicken embryos 
depends on the concentration and developmental stage [54]. The Spearman’s correlation coef-
ficient was greater than 0.976 at p < 0.001, which indicates a high dependence. It is known that 
iodides can exhibit toxicity to the reproductive function in two ways: through oxidative stress 
in the testis of rats and thyroid dysfunction in pregnant females [52, 55].
One of the problems encountered in the clinical trials of new drugs is that there could be 
various unforeseen immunotoxic reactions [56, 57]. As already noted, iodine complexes have 
immunotropic properties [15, 58]. Therefore, the immunotoxicity and allergenicity of FS-1 
were studied in various tests:
a. Intradermal and conjunctival test
b. Active and passive (ovary) cutaneous anaphylaxis
c. mast cell degranulation
d. Anaphylactogenicity
e. Induction of delayed-type hypersensitivity reaction
f. Analysis of changes in mass and cellularity of the popliteal lymph node
g. Assessment of specific lysis of human peripheral blood leukocytes
h. Analysis of the relative count of basophils and eosinophils in human peripheral blood
i. Determination of mass and cellularity of immune organs and antibody response in guinea 
pigs
The study found that FS-1 does not possess anaphylactogenicity, does not cause type I allergic 
reaction and does not influence the formation of a delayed-type hypersensitivity reaction, 
does not have immunopathological and immunotoxic effects, and does not cause disorders 
and/or dysfunctions in the processes involved in normal maintenance of immune status in the 
tested doses, even against the background of antigenic stimulus [59, 60].
The preparation of a tablet dosage form of FS-1 is the most important stage in the pharmaceu-
tical development of novel drug [34, 61, 62].
After the oral administration of FS-1 tablets to rats (Wistar), LD
50
 was found to exceed 
2000 mg/kg [43]. The observed clinical and pathomorphological signs of damage to the body 
of animals with FS-1 are similar to the symptoms of poisoning with iodine solutions [50]. 
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Toxicology of iodides and iodates was well studied in numerous animal species, as well as in 
humans, whereas the data on iodine complexes including Lugol’s solution and PVP-iodine 
are very scarce [51, 63].
The toxicity of FS-1 tablets associated with repeated administration was examined in rats 
(Wistar) after 28-day oral administration. It was found that the organs for the damaging 
action of FS-1 included the thyroid gland, liver, and kidneys. There were changes in the blood 
parameters: the levels of leukocytes and lymphocytes and alanine aminotransferase and 
aspartate aminotransferase increased. But these changes were reversible, and after 28 days of 
recovery period, all parameters were normalized [43].
It is known that prolonged exposure to or intake of high doses of the iodine-containing drugs 
is accompanied by thyrotoxic reactions in the form of iodine-induced hypothyroidism [64]. 
Due to excessive intake of iodine, the Wolff-Chaikoff effect occurs, which develops within a 
few days [65]. This is accompanied by a temporary reduction of the thyroid hormone level due 
to a decrease in the Na+/I-symporter activity (NIS) [66]. The Wolff-Chaikoff effect is transient, 
and the level of hormones with the withdrawal of the iodine-containing drugs is restored 
in a few days. It was noted that the chronic effect of iodine doses (in Japan, for example, up 
to several milligrams per day are consumed with food, exceeding the WHO recommended 
standards (90–200 μg)) frequently does not cause any hypothyroid or thyrotoxic conditions 
[67]. Therefore, rats were also analyzed for the level of thyroid-stimulating hormone (TSH), 
thyroxine (T4), and triiodothyronine (T3). The findings of the studies have shown that the lev-
els of TSH, T3, and T4 in the blood serum of rats did not change. It has been established that 
the T3/T4 ratio in all studied groups was in the range of 0.20–0.50. The absence of significant 
changes in the T3/T4 ratio in animals of all groups indicates a normal rate of deiodization. As 
a result, the highest nontoxic dose (NOAEL) of FS-1 was established, which was of 100 mg/kg 
[43]. Summarizing the results obtained, it can be noted that high doses of FS-1 lead to the 
development of thyrotoxicosis in rats and not hypothyroidism, as with excessive intake of 
iodides into the animal organism [51].
5. Conclusion
FS-1 is highly effective against various Gram-positive and Gram-negative bacteria, includ-
ing those resistant to antibiotics. MIC varied over a wide range from 0.02 to 0.3 mg/mL. At 
that, FS-1 has a synergistic effect with some antimicrobial agents. The main mechanism of 
action of FS-1 consists in membrane lytic activity. In addition, the investigational drug affects 
the gene expression in bacteria. The effectiveness of FS-1 in combination with ATBD of the 
first- and second-line was examined in the guinea pig models of tuberculosis. FS-1 has pro-
nounced anti-inflammatory and antitoxic effects. The CC
50
 value in MDCK cells is more than 
5 mg/mL. This is 16 times higher than the MIC. FS-1 does not have mutagenic and genotoxic 
properties. The acute oral toxicity of FS-1 in rats is LD
50
 of more than 2000 mg/kg. The extent 
of FS-1 distribution in the organs is not greater than in the blood. Its kinetics is linear. The 
primary metabolites include iodides. At the same time, FS-1 possesses embryonic toxicity in 
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chicken embryos but does not lead to developmental abnormalities. FS-1 does not cause aller-
gic reactions and does not possess immunotoxic properties. The liver, kidney, and thyroid 
gland are the target organs for toxic injuries induced by repeated administration of FS-1. At 
the same time, thyrotoxicosis develops but not hypothyroidism. NOAEL value is 100 mg/kg 
of rats after 28-day oral administration and 30 mg/kg in rabbits after 180-day administration.
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